Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies

Figure 3

OS analysis of the CD5 and CD6 ratios in the training and validation cohorts. (a-b) OS analysis was performed with the dichotomized relative expression ratios of CD5/CD3E, CD5/CD3G, CD5/CD3D, CD5/CD247, CD5/CD4, CD5/CD8A, CD5/CD8B (a) and the CD6/CD3E, CD6/CD3G, CD6/CD3D, CD6/CD247, CD6/CD4, CD6/CD8A, CD6/CD8B ratios (b) in the training (left panel) and validation (right panel) cohorts.

(a)

(b)